It's been a frantic week on the work front and today was no different, but I wanted to highlight a really interesting slide from the BMS pipeline presentation yesterday afternoon.
Here's one of the slides Elliot Sigal, President of R&D, showed from one of the ipilimumab trials. More data may be available at ASCO if the submitted abstract is accepted, but for now, even though it's only an n of 1, a picture tells a thousand words:
After all the recent good news about malignant melanoma, hopefully at least one of these promising agents will make it to market in the not too distant future, offering people suffering with the condition a glimmer of hope. I sincerely hope the CTLA4 results turn out to be durable.
In the meantime, we can all wonder until June, when the annual ASCO meeting will held.